Baxter Supports Analysis Demonstrating Clinical and Economic Benefits of Effective Intraoperative Blood Management for Surgical Patients

Author's Avatar
Jul 15, 2021

Baxter International Inc. (NYSE:BAX, Financial), a global leader in advancing surgical innovation, recognizes the findings of a large+retrospective+observational+analysis+published+in+the+%3Ci%3EJournal+of+Medical+Economics%3C%2Fi%3E. The Baxter-sponsored analysis demonstrated that the use of active hemostatic products alone was associated with lower rates of bleeding-related complications, shorter hospital stays and reduced total hospital costs compared to combined use of passive and active hemostats in inpatient procedures across multiple surgical specialties.